-
Salivary Therapeutic Monitoring of Buprenorphine in Neonates After Maternal Sublingual Dosing Guided by Physiologically Based Pharmacokinetic Modeling. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-02-16 Mo'tasem M Alsmadi
Opioid use disorder (OUD) during pregnancy is associated with high mortality rates and neonatal opioid withdrawal syndrome (NOWS). Buprenorphine, an opioid, is used to treat OUD and NOWS. Buprenorphine active metabolite (norbuprenorphine) can cross the placenta and cause neonatal respiratory depression (EC50 = 35 ng/mL) at high brain extracellular fluid (bECF) levels. Neonatal therapeutic drug monitoring
-
Dose Monitoring of Lamotriginxe Monotherapy in Pregnancy: Are Pregnant Women with Epilepsy Currently Optimally Managed? A Systematic Review. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-02-16 Yeonkyung Goo, Anne Marijn der Nederlanden, Andrew Bleasel, Jan-Willem Alffenaar, Hannah Yejin Kim
Lamotrigine monotherapy is the first-line treatment for epilepsy in pregnant women. However, altered pharmacokinetics during pregnancy can lead to suboptimal drug levels and increased seizure risk. This systematic review aimed to evaluate current therapeutic drug monitoring (TDM) strategies for lamotrigine monotherapy in pregnant women with epilepsy and provide guidance for monitoring and dose adjustments
-
Assessing Pharmacokinetic Correlates of Escitalopram-Related Adverse Drug Reactions. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-02-06 Maxim Kuzin, Ekkehard Haen, Nazar Kuzo, Katharina Endres, Christoph Hiemke, Michael Paulzen, Georgios Schoretsanitis
To assess the pharmacokinetic correlates of reported adverse drug reactions (ADRs) under antidepressant treatment with escitalopram (ESC) using a large therapeutic drug monitoring database.
-
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-02-06 Bianca Posocco, Martina Zanchetta, Marco Orleni, Sara Gagno, Marcella Montico, Elena Peruzzi, Rossana Roncato, Lorenzo Gerratana, Serena Corsetti, Fabio Puglisi, Giuseppe Toffoli
Therapeutic drug monitoring (TDM) using cyclin-dependent kinase inhibitors (CDK4/6is) is a novel approach for optimizing treatment outcomes. Currently, palbociclib, ribociclib, and abemaciclib are the available CDK4/6is and are primarily coadministered with letrozole. This study aimed to develop and validate an LC-MS/MS method for the simultaneous analysis of CDK4/6is, 2 active metabolites of abemaciclib
-
Unveiling the Rare Presentation of Acetylsalicylate Overdose: Grand Round. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-02-06 Saeko Kohara, Yoshito Kamijo, Ryoko Kyan, Tsuyoshi Hishikawa, Ichiro Okada, Eiju Hasegawa
This case report highlights a rare occurrence of aspirin overdose presenting only as severe coagulopathy.
-
Analytical Validation of a Volumetric Absorptive Microsampling Method for Therapeutic Drug Monitoring of the Oral Targeted Anticancer Agents, Abiraterone, Alectinib, Cabozantinib, Imatinib, Olaparib, and Sunitinib, and Metabolites. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-30 Marinda Meertens, Niels de Vries, Hilde Rosing, Neeltje Steeghs, Jos H Beijnen, Alwin D R Huitema
Volumetric Absorptive Microsampling (VAMS) is a useful tool for therapeutic drug monitoring (TDM) of oral targeted anticancer agents. VAMS aims to improve safety and efficacy by enabling at-home blood sample collection by patients. This study aimed to develop and validate an ultra-high performance liquid chromatography-tandem mass spectrometry method for the quantitative determination of abiraterone
-
Changes in Psychotropic Drug Concentrations Across the Menstrual Cycle: A Pilot Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-30 Julia Spadi, Maike Scherf-Clavel, Anna Linda Leutritz, Barbara Hütz, Maria Matentzoglu, Matthias Nieberler, Max Kurlbaum, Stefanie Hahner, Catharina Bartmann, Rhiannon V McNeill, Sarah Kittel-Schneider
The escalating prescription of psychopharmacological medications to women of reproductive age underscores the growing significance of sex-specific variations in pharmacotherapy. Despite this, clinical trials have largely overlooked these differences. Preliminary data indicate sex-specific variations in the neurobiology of affective disorders and in the metabolism, pharmacodynamics, and kinetics of
-
Factors Influencing Plasma Concentrations of Valproic Acid in Pediatric Patients with Epilepsy and the Clinical Significance of CYP2C9 Genotypes in Personalized Valproic Acid Therapy. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-26 Bingsuo Ma, Kun Yang, Xinping Li, Ning Su, Ting Yu, Yan Zou, Xingmeng Xu, Fei Wang, Jingdong Cheng, Zijun Yan, Tong Chen, Liangming Zhang
The aim of this study was to investigate the factors affecting plasma valproic acid (VPA) concentration in pediatric patients with epilepsy and the clinical significance of CYP2C9 gene polymorphisms in personalized dosing using therapeutic drug monitoring and pharmacogenetic testing.
-
Novel Identification of Cysteinyl Derivatives of Toxic Clozapine Nitrenium Ions and the Effect of Valproic Acid on Metabolite Formation: A Study Using Reprocessed High-Resolution Mass Spectra of Analyzed Therapeutic Drug Monitoring Samples. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-26 Birgit M Wollmann, Aina G Haugen, Robert L Smith, Espen Molden
Clozapine (CLZ) use is hampered by the risk of granulocyte toxicity, which is associated with the formation of nitrenium ions and the concurrent use of valproic acid (VPA). These highly reactive nitrenium ions cannot be measured in vivo. Instead, deactivated cysteinyl conjugates may potentially be detected. The aim of this study was to develop a novel method for identifying cysteinylated derivates
-
Fluorescence-Based Lateral Flow Immunoassay for Quantification of Infliximab: Analytical and Clinical Performance Evaluation. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-26 Eun Sil Kim, Hyangah Chon, Yiyoung Kwon, Misook Lee, Mi Jin Kim, Yon Ho Choe
Therapeutic drug monitoring of infliximab (IFX) can improve treatment outcomes; however, the temporal gap between drug concentration monitoring and subsequent availability restricts its practical application. To address this issue, an automated monitoring method, AFIAS IFX, was developed to rapidly and accurately analyze IFX concentration in blood. The analytical and clinical performances of this method
-
Analysis of Factors Affecting Concentrations and Concentration-To-Dose Ratios of Trazodone. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-26 Yang Song, Luyao Chang, Yang Lun, Chaoli Chen, Ran Fu, Donghan Wang, Chunhua Zhou
Trazodone is prescribed for several clinical conditions. Multiple factors may affect trazodone to reach its therapeutic reference range. The concentration-to-dose (C/D) ratio can be used to facilitate the therapeutic drug monitoring of trazodone. The study aimed to investigate factors on the concentrations and C/D ratio of trazodone.
-
Predictive Performance of a Gentamicin Pharmacokinetic Model in Term Neonates with Perinatal Asphyxia Undergoing Controlled Therapeutic Hypothermia. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-24 Marlotte A A van der Veer, Timo R de Haan, Linda G W Franken, Floris Groenendaal, Peter H Dijk, Willem P de Boode, Sinno Simons, Koen P Dijkman, Henrica L M van Straaten, Monique Rijken, Filip Cools, Debbie H G M Nuytemans, Anton H van Kaam, Yuma A Bijleveld, Ron A A Mathôt
Model validation procedures are crucial when population pharmacokinetic (PK) models are used to develop dosing algorithms and to perform model-informed precision dosing. We have previously published a population PK model describing the PK of gentamicin in term neonates with perinatal asphyxia during controlled therapeutic hypothermia (TH), which showed altered gentamicin clearance during the hypothermic
-
Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-24 Femke Hooijberg, Zohra Layegh, Maureen Leeuw, Laura Boekel, Stefan P H van den Berg, Jill Ruwaard, Carla Bastida, Alwin D R Huitema, Sara Pel, Ori Elkayam, Annick de Vries, Mike Nurmohamed, Theo Rispens, Thomas P C Dorlo, Gertjan Wolbink
Tocilizumab in the treatment of rheumatoid arthritis (RA) is a potential candidate for concentration-guided tapering because the standard dose of tocilizumab results in a wide range of serum concentrations, usually above the presumed therapeutic window, and an exposure-response relationship has been described. However, no clinical trials have been published to date on this subject. Therefore, the objective
-
Update Lessons from PET Imaging Part II: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antidepressants. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-24 Xenia M Hart, Moritz Spangemacher, Julie Defert, Hiroyuki Uchida, Gerhard Gründer
Compared with antipsychotics, the relationship between antidepressant blood (plasma or serum) concentrations and target engagement is less well-established.
-
Development, Validation, and Clinical Application of an Ultra-High-Performance Liquid Chromatography Coupled With Tandem Mass Spectrometry Method for the Determination of 10 Antituberculosis Drugs in Human Serum. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-24 Xudong Fan, Suhang Guo, Ruoying Zhang, Qingshan Cai, Yazhen Lang, Jinpeng Huang, Yuanyuan Chen, Ying Zhang, Yingying Xu, Meng Chen, Gaoyi Yang, Xinjun Cai
Linezolid, moxifloxacin, rifapentine, rifabutin, cycloserine, clofazimine, bedaquiline, levofloxacin, prothionamide, and ethionamide are commonly used second-line antituberculosis (anti-TB) drugs. To support therapeutic drug monitoring in regular clinical practice, the authors sought to develop a method based on ultra-high-performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS)
-
Correlation Between N-Demethyl Imatinib Trough Concentration and Serious Adverse Reactions in Patients with Gastrointestinal Stromal Tumors: A Retrospective Cohort Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2024-01-04 Mingfeng Liu, Teng Guo, Zhixue Ma, Liying Du, Juan Hou, Yuan Tian, Meng Meng, Xinran Chen
Imatinib is the first-line treatment for gastrointestinal stromal tumors; however, the clinical prognosis and adverse reactions of patients vary owing to individualized discrepancies in plasma exposure.
-
Effects of Wuzhi Capsule on Whole-Blood Tacrolimus Concentration Levels: A Systematic Review and Meta-Analysis. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-12-27 Chunyan Zhang, Xiaolei Ren, Yi Liu, Lin Huang, Yufei Feng, Xiaohong Zhang
Wuzhi Capsule (WZC) is a traditional Chinese medicinal herb widely used to treat drug-induced hepatitis or liver dysfunction and is usually prescribed in China to increase tacrolimus concentration. Several studies with small sample sizes have shown that WZC can increase tacrolimus concentration levels in clinical practice. This study aimed to evaluate the effect of WZC on whole-blood tacrolimus concentration
-
Implementation Strategies Addressing Stakeholder-Perceived Barriers and Enablers to the Establishment of a Beta-Lactam Antibiotic Therapeutic Drug Monitoring Program: A Qualitative Analysis. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-28 Rekha Pai Mangalore, Andrew Alexander Udy, Trisha Nicole Peel, Anton Yariv Peleg, Darshini Ayton
Therapeutic drug monitoring (TDM) of beta-lactam antibiotics (beta-lactams) is increasingly recommended for optimizing antibiotic exposure in intensive care patients with sepsis. However, limited data are available on the implementation of beta-lactam TDM in complex health care settings. Theory-based approaches were used to systematically explore barriers and enablers perceived by key stakeholders
-
Therapeutic Drug Level Monitoring of Antipsychotics at an Inpatient Psychiatric Hospital. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-28 Nisha Chandrakant Bhavsar, Julie Ann Dopheide, Timothy Eugene Botello, Mengxi Wang
The American Psychiatric Association guidelines for the treatment of patients with schizophrenia state that the utility of antipsychotic therapeutic drug monitoring (TDM) remains unclear, except for clozapine or assessing adherence. The aim of this study was to investigate the extent and impact of antipsychotic TDM in inpatient practice to improve its utilization.
-
Effect of Metformin on Plasma Exposure of Rifampicin, Isoniazid, and Pyrazinamide in Patients on Treatment for Pulmonary Tuberculosis. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-28 Agibothu Kupparam Hemanth Kumar, Abhijit Kadam, Ramesh Karunaianantham, Manoharan Tamizhselvan, Chandrasekaran Padmapriyadarsini, Anant Mohan, B Jeyadeepa, Ammayappan Radhakrishnan, Urvashi B Singh, Shraddha Bapat, Aarti Mane, Pradeep Kumar, Megha Mamulwar, Perumal Kannabiran Bhavani, Hemalatha Haribabu, Nibedita Rath, Randeep Guleria, Abdul Mabood Khan, Jaykumar Menon
To evaluate the effect of metformin on the plasma levels of rifampicin, isoniazid, and pyrazinamide in patients with drug-sensitive pulmonary tuberculosis being treated with first-line antituberculosis treatment (ATT) and to assess the influence of gene polymorphisms on the metabolic pathway of metformin and plasma levels of antitubercular drugs.
-
A Validated Assay to Quantify Osimertinib and Its Metabolites, AZ5104 and AZ7550, from Microsampled Dried Blood Spots and Plasma. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Bharat Venkatesh, Alex Yuile, Matthew J McKay, Sathya Narayanan, Helen Wheeler, Malinda Itchins, Nick Pavlakis, Stephen J Clarke, Mark P Molloy
Osimertinib is an oral small-molecule tyrosine kinase receptor inhibitor used to treat non-small cell lung cancer (NSCLC) with a sensitizing epidermal growth factor receptor mutation. Patients may experience drug toxicity and require dose deescalation. The study aimed to quantitate osimertinib and its 2 active metabolites, AZ5104 and AZ7550, in microsampled dried blood spots (DBS) collected from patients
-
Clinical Guidance for Dosing and Monitoring Oral Antihormonal Drugs in Patients with Breast Cancer After Roux-en-Y Gastric Bypass. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Jurjen S Kingma, Niels W L Peeters, Catherijne A J Knibbe, Mariette J Agterof, Wouter J M Derksen, Desirée M T Burgers, Marcel P H van den Broek
Obesity is associated with an increased risk of cancers, such as breast cancer. Roux-en-Y gastric bypass (RYGB) is a common surgical intervention used to induce weight loss, reduce comorbidities, and improve overall survival. Due to alterations in the gastrointestinal tract, RYGB is associated with changes in oral drug disposition, which can affect treatment outcomes. Oral antihormonal agents were
-
Update Lessons from Positron Emission Tomography Imaging Part I: A Systematic Critical Review on Therapeutic Plasma Concentrations of Antipsychotics. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Xenia M Hart, Moritz Spangemacher, Hiroyuki Uchida, Gerhard Gründer
Positron emission tomography (PET) and single photon emission tomography (SPECT) of molecular drug targets (neuroreceptors and transporters) provide essential information for therapeutic drug monitoring-guided antipsychotic drug therapy. The optimal therapeutic windows for D2 antagonists and partial agonists, as well as their proposed target ranges, are discussed based on an up-to-date literature search
-
Evaluation for Blood Concentration and Efficacy/Safety of Continuous Administration of Thiamylal in Children. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Kenshiro Hirata, Takafumi Obara, Tokunori Ikeda, Hiroshi Watanabe, Issei Fujita, Hirokazu Furusho, Takako Ishiguro, Sachiko Jingami, Toru Maruyama, Katsuki Hirai, Shigeyuki Miyamura
Thiamylal exerts excellent sedative effects. However, it is not routinely used because of its serious adverse effects. This study aimed to clarify the target blood concentration range and infusion rate of thiamylal in children by measuring its blood concentration and evaluating its relationship with efficacy and adverse effects.
-
Comprehensive Monitoring of Psychoactive Substances in Psychiatric Patients Using Liquid Chromatography-High-Resolution Mass Spectrometry: A Key Tool for Treatment Planning and Understanding Consumption Patterns in Rome, Italy. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Nunzia La Maida, Alessandro Di Giorgi, Simona Pichini, Manuela Pellegrini, Annagiulia Di Trana, Maria Giuseppa Elmo, Gian Marco Polselli, Pietro Casella, Adele Di Stefano, Giuseppe Ducci
The comprehensive monitoring of licit and illicit drug consumption plays a crucial role in understanding the complexities of patient conditions and designing effective treatment strategies. In this study, the prevalence of psychoactive prescription drugs, classical illicit drugs, and new psychoactive substances (NPS) were objectively assessed in individuals diagnosed with drug-related psychiatric disorders
-
A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus for Tunisian Adults after Renal Transplantation. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Amani Abderahmene, Marith I Francke, Louise M Andrews, Dennis A Hesselink, Dorra Amor, Wissal Sahtout, Marwa Ajmi, Hayfa Mastouri, Ali Bouslama, Dorsaf Zellama, Asma Omezzine, Brenda C M De Winter
Tacrolimus is the most frequently used immunosuppressive drug for preventing renal rejection. However, its use is hampered by its narrow therapeutic index and large intra and interpatient variability in pharmacokinetics. The objective of this study was to externally validate a tacrolimus population pharmacokinetic model developed for the Dutch population and adjust the model for the Tunisian population
-
Therapeutic Drug Monitoring to Optimize Risperidone Treatment in Children with Autism Spectrum Disorder. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-27 Rebecca A Hermans, Alaya E M Storm, Sanne M Kloosterboer, Manon H J Hillegers, Birgit C P Koch, Bram Dierckx, Brenda C M de Winter
Risperidone is an atypical antipsychotic drug used to treat irritability and aggression in children and adolescents with autism spectrum disorder. In an earlier study, the sum trough concentration of risperidone and its metabolite (9-hydroxyrisperidone) was positively correlated with weight gain and effectiveness. The aim of this study was to determine the therapeutic window for risperidone sum trough
-
Fast and Sensitive Analysis of Fosfomycin in Human Plasma Microsamples Using Liquid Chromatography-Tandem Mass Spectrometry for Therapeutic Drug Monitoring. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-22 Rossella Barone, Matteo Conti, Beatrice Giorgi, Milo Gatti, Pier Giorgio Cojutti, Pierluigi Viale, Federico Pea
Fosfomycin is an antibiotic recently repurposed as a potential combination treatment for difficult-to-treat Gram-negative bacterial infections. The pharmacokinetic features of fosfomycin have demonstrated that different pathophysiologic alterations may affect its exposure. Therapeutic drug monitoring may improve real-time management of fosfomycin therapy in different clinical scenarios.
-
A Systematic Critical Review of Clinical Pharmacokinetics of Torasemide. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-17 Abdul Wasay Sherazi, Ammara Zamir, Anees Ur Rehman, Waseem Ashraf, Imran Imran, Hamid Saeed, Abdul Majeed, Zikria Saleem, Majid Aziz, Faleh Alqahtani, Muhammad Fawad Rasool
Torasemide is a potassium-sparing loop diuretic used to treat fluid retention associated with congestive heart failure and kidney and hepatic diseases. This systematic review was conducted to combine all accessible data on the pharmacokinetics (PK) of torasemide in healthy and diseased populations, which may help clinicians avert adverse drug reactions and determine the correct dosage regimen.
-
A Systematic Review of Clozapine Concentration-Dose Ratio from Therapeutic Drug Monitoring Studies in Children and Adolescents Treated with Clozapine for Mental Disorders. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-16 Sara Jiménez-Fernández, Manuel Gurpegui, Christoph U Correll, Jose de Leon, Georgios Schoretsanitis
Therapeutic drug monitoring of clozapine in children and adolescents has received insufficient attention. Calculation of concentration-to-dose (C/D) ratios from trough steady-state concentrations estimate drug clearance.
-
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-15 Nicole F Maranchick, Cesar Trillo-Alvarez, Vidhu Kariyawasam, Veena Venugopalan, Awewura Kwara, Kenneth Rand, Charles A Peloquin, Mohammad H Alshaer
Antimicrobial resistance is a growing health concern worldwide. The objective of this study was to evaluate the effect of beta-lactam infusion on the emergence of bacterial resistance in patients with severe pneumonia in the intensive care unit.
-
Recommendation for a Therapeutic Reference Range of Cariprazine-A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-14 Fabian Sattaf, Maike Scherf-Clavel, Stefan Unterecker, Andreas Reif, Martina Hahn
Therapeutic reference ranges are essential for therapeutic drug monitoring to evaluate results and adjust pharmacotherapy. The measured serum concentrations of cariprazine-treated patients have frequently been found to lie beyond the currently used therapeutic reference range; furthermore, reliable data for establishing evidence-based therapeutic ranges are scarce. The current therapeutic reference
-
Pharmacobezoar-Related Fatalities: A Case Report and a Review of the Literature. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-08 Guillaume Drevin, Stéphane Malbranque, Nathalie Jousset, Séverine Férec, Donca Zabet, Antoine Baudriller, Marie Briet, Chadi Abbara
Pharmacobezoars develop after an acute overdose or during routine drug administration. Here, the authors present a case of fatal multidrug overdose involving a 62-year-old woman. Her usual treatment included tramadol extended-release, citalopram, and mirtazapine. Furthermore, she self-medicated and misused her husband's medications. The autopsy revealed the presence of a voluminous medication bezoar
-
Pharmacokinetic Consideration of Venetoclax in Acute Myeloid Leukemia Patients: A Potential Candidate for TDM? A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-11-08 Michael Philippe, Jérôme Guitton, Sylvain Goutelle, Yann Thoma, Bertrand Favier, Nour Chtiba, Mauricette Michallet, Amine Belhabri
Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a fixed dose, irrespective of body surface area or weight. For such orally targeted therapies, real-world data have highlighted a larger pharmacokinetic (PK) interindividual variability
-
Sample Matrices for Mass Spectrometry-Based Adherence Monitoring: A Systematic Critical Review. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-10-05 Cathy M Jacobs, Lea Wagmann, Markus R Meyer
Analytical monitoring of adherence using mass spectrometry (MS) plays an important role in clinical toxicology. Unambiguous detection of drugs (of abuse) and/or their metabolites in body fluids is needed to monitor intake of medication as prescribed or to monitor abstinence as a follow-up to detoxification procedures. This study focused on the advantages and disadvantages of different sample matrices
-
Population Pharmacokinetics of Topiramate in Patients with Epilepsy Using Nonparametric Modeling. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-10-04 Mandy Elewa, Sarah S Alghanem, Jasem Al-Hashel, Anil Thussu, Yousef Al-Lanqawi, Kamal Matar
Topiramate (TPM) is used for the treatment of various epileptic seizures and the prevention of migraine. This study aimed to develop a population pharmacokinetic model and identify covariates that influence TPM behavior in patients with epilepsy in Kuwait.
-
Determining Plasma Tacrolimus Concentrations Using High-Performance LC-MS/MS in Renal Transplant Recipients. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-26 Mirabel Alonge, Janet K Coller, Stephanie E Reuter, Shilpanjali Jesudason, Benedetta C Sallustio
Whole-blood therapeutic drug monitoring of tacrolimus is conducted to maintain tacrolimus concentrations within a safe and effective range. Changes in hematocrit cause variability in blood concentrations of tacrolimus because it is highly bound to erythrocytes. Measuring plasma concentrations may eliminate this variability; however, current methods have limitations owing to the use of cross-reactive
-
Plasma Concentration, Efficacy, and Tolerability of Perampanel in Chinese Pediatric Patients with Epilepsy: Real-World Clinical Experience. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-25 Ting Zhao, Hong-Jian Li, Hui-Lan Zhang, Ji-Rong Feng, Jing Yu, Jie Feng, Ting-Ting Wang, Yan Sun, Lu-Hai Yu
Information on the efficacy and plasma concentration of perampanel (PER) in Chinese pediatric patients with epilepsy is limited. Therefore, this real-world retrospective study aimed to assess the efficacy, tolerability, and plasma concentration of the maximum dose of PER for epilepsy treatment in Chinese pediatric patients.
-
A Novel LC-MS/MS Method for Therapeutic Drug Monitoring of Baricitinib in Plasma of Pediatric Patients. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-25 Alessia Cafaro, Giammarco Baiardi, Federica Pigliasco, Sebastiano Barco, Francesca Mattioli, Stefano Volpi, Roberta Caorsi, Marco Gattorno, Giuliana Cangemi
Janus kinase inhibitors are antirheumatic immunosuppressive drugs that target intracellular Janus kinases (JAKs). Baricitinib is a selective and reversible orally administered JAK1/JAK2 inhibitor approved for treating rheumatoid arthritis, atopic dermatitis, and alopecia areata in adult patients. Expanded access to baricitinib has been approved for treating pediatric patients affected by rare Mendelian
-
Dose Individualization of Cefepime for Febrile Neutropenia in Patients With Lymphoma or Multiple Myeloma: Implications for Therapeutic Drug Monitoring. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-18 Kazutaka Oda, Ayami Yamaguchi, Naoya Matsumoto, Hirotomo Nakata, Yusuke Higuchi, Kisato Nosaka, Hirofumi Jono, Hideyuki Saito
Optimal cefepime dosing is a challenge because of its dose-dependent neurotoxicity. This study aimed to determine individualized cefepime dosing for febrile neutropenia in patients with lymphoma or multiple myeloma.
-
Ceftriaxone Pharmacokinetics and Pharmacodynamics in 2 Pediatric Patients on Extracorporeal Membrane Oxygenation Therapy. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-12 Francisco C Cervantes, Tomoyuki Mizuno, Min Dong, Peter Tang, Trent Arbough, Alexander A Vinks, Jennifer M Kaplan, Sonya C Tang Girdwood
Critically ill patients with cardiac or respiratory failure may require extracorporeal membrane oxygenation (ECMO). Antibiotics are frequently administered when the suspected cause of organ failure is an infection. Ceftriaxone, a β-lactam antibiotic, is commonly used in patients who are critically ill. Although studies in adults on ECMO have suggested minimal impact on ceftriaxone pharmacokinetics
-
Simultaneous Quantification of Psychotropic Drugs in Human Plasma and Breast Milk and Its Application in Therapeutic Drug Monitoring and Peripartum Treatment Optimization. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-06 Marguerite Le Marois, Natalia Doudka, Eleni Tzavara, Laurence Delaunay, Sylvie Quaranta, Olivier Blin, Raoul Belzeaux, Romain Guilhaumou
Therapeutic drug monitoring is recommended for several psychotropic drugs, particularly in sensitive situations such as the peripartum period. This study aimed to develop an ultra-high-performance liquid chromatography-tandem spectrometry method for the simultaneous quantification of 14 psychotropic drugs in human plasma and 4 in breast milk.
-
PEG 400 Ion Suppression in Busulfan Detection by High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-06 Simona De Gregori, Mara Capone, Annalisa De Silvestri, Riccardo Albertini
Busulfan (Bu), an alkylating agent commonly used in chemotherapy and transplantation, exhibits high intraindividual pharmacokinetic variability and possible time-dependent variations in clearance, which complicate therapeutic drug monitoring. Numerous analytical methods have been developed to reduce analysis time and facilitate timely decision-making regarding treatment changes; however, the validation
-
3-Methylmethcathinone Intoxication: Discrepancies Between Blood Concentrations and Clinical Outcomes-A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-09-04 Guillaume Drevin, Antoine Baudriller, Severine Ferec, François Beloncle, Marie Briet, Chadi Abbara
The absence of a correlation between the blood concentration of 3-methylmethcathinone (3-MMC) and clinical outcomes in intoxication cases has been attributed to stability issues. Indeed, a loss of more than 50%, 70%, and even 95% of 3-MMC in whole blood after 2 weeks of storage at 20°C, 4°C, and room temperature, respectively, has been reported in the past. Here, the authors report the case of a 43-year-old
-
Levomethadone Therapeutic Drug Monitoring to Aid Opioid Withdrawal Therapy: A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-08-29 Philippe Pfeifer, Kathrin Hildebrand, Andreas Angelov, Ursula Havemann-Reinecke, Michael Böttcher, Christoph Hiemke, Tatjana Prentice, Sibylle C Roll
Therapeutic drug monitoring (TDM) is recommended for opioid maintenance therapy with levomethadone. However, TDM has not yet been applied to monitor opioid withdrawal therapy clinically, although tools to improve it are required.
-
Matrix Effects of Urine Marker Substances in LC-MS/MS Analysis of Drug of Abuse. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-08-23 Bernd Huppertz, Silke Möller-Friedrich, Klaus Baum
Analysis of drug abuse is frequently performed using high-performance liquid chromatography with an MS/MS detector and electrospray ionization. In this context, matrix effects, like signal reduction by ion suppression of individual analytes, play an important role. In this study, the authors evaluated the matrix effect caused by polyethylene glycol (PEG) with chain lengths ranging from 6 to 12 repeating
-
Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-08-15 Fumiaki Tanaka, Kei Irie, Nobuyuki Fukui, Ryo Horii, Hirotoshi Imamura, Masaki Hirabatake, Hiroaki Ikesue, Nobuyuki Muroi, Shoji Fukushima, Nobuyuki Sakai, Tohru Hashida
Temozolomide (TMZ) is an alkylating agent used to treat glioblastoma. However, the pharmacokinetics of TMZ to establish a treatment strategy for patients undergoing hemodialysis (HD) remain unclear. In this case report, we evaluated the pharmacokinetics and HD removal rate of TMZ in a patient with glioblastoma undergoing HD to determine optimal dosing of TMZ.
-
Systematic Critical Review of Genetic Factors Associated with Cisplatin-induced Ototoxicity: Canadian Pharmacogenomics Network for Drug Safety 2022 Update. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-07-13 Erika N Scott, Akshaya A Joseph, Angie Dhanda, Reo Tanoshima, Beth Brooks, S Rod Rassekh, Colin J D Ross, Bruce C Carleton, Catrina M Loucks
Cisplatin is commonly used to treat solid tumors; however, its use can be complicated by drug-induced hearing loss (ie, ototoxicity). The presence of certain genetic variants has been associated with the development/occurrence of cisplatin-induced ototoxicity, suggesting that genetic factors may be able to predict patients who are more likely to develop ototoxicity. The authors aimed to review genetic
-
Limited Sampling Strategy Using End of Infusion and Six-Hour Concentrations Overestimates Intravenous Busulfan Clearance Compared With Standard Six-Point Sampling in Hematopoietic Stem Cell Transplant Patients. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-07-13 Bushra Mustafa Salman, Intisar Mohammed Al Riyami, Aya Hasan AalHamad, Murtadha Al-Khabori
Therapeutic drug monitoring for busulfan (Bu) is important to improve outcomes of hematopoietic stem cell transplantation. However, standard therapeutic drug monitoring requires multiple samples and is inconvenient, labor-intensive, and costly. Accordingly, a limited sampling strategy (LSS) was evaluated, using 2-point sampling at end of infusion and at 6 hours, and the area-under-the-curve and Bu
-
Ceftazidime Plasma Concentrations and Neurotoxicity: The Importance of Therapeutic Drug Monitoring in Patients Undergoing Different Modalities of Renal Replacement Therapy. A Grand Round. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-07-03 Roselle S Robosa, Cindy Lau, Jana Stojanova, Cheau Wern Chin, Deborah J E Marriott
Ceftazidime-avibactam (CTZ-AVM) is a novel cephalosporin/beta-lactamase inhibitor with broad-spectrum activity against multidrug-resistant Pseudomonas aeruginosa. Ceftazidime-induced neurotoxicity is a well-described adverse effect, particularly in patients with renal insufficiency. However, appropriate dosing of ceftazidime-avibactam in patients undergoing renal replacement therapy (RRT) is sparsely
-
Effects of Sleeve Gastrectomy and Roux-en-Y Gastric Bypass on Escitalopram Pharmacokinetics: A Cohort Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-15 Georgios Schoretsanitis, Magnus Strømmen, Hege-Merete Krabseth, Arne Helland, Olav Spigset
Changes in the gastrointestinal physiology after bariatric surgery may affect the pharmacokinetics of medications. Data on the impact of different surgical techniques on the pharmacokinetics of commonly prescribed antidepressants such as escitalopram are limited.
-
Effect of Tacrolimus Time in Therapeutic Range on Postoperative Recurrence in Patients Undergoing Liver Transplantation for Liver Cancer. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-13 Qianying Lao, Xuanyu Wu, Xinxin Zheng, Jinwei Hu, Siqi Huang, Danying Li, Yao Du, Na Yang, Huaijun Zhu
Liver cancer is the second highest cause of cancer-related deaths worldwide. It is commonly treated with liver transplantation, where tacrolimus is typically used as an antirejection immunosuppressant. The purpose of this study was to evaluate the effect of tacrolimus time in therapeutic range (TTR) on liver cancer recurrence in liver transplant recipients and to compare the performance of TTRs calculated
-
Using Prior Knowledge on Systems Through PBPK to Gain Further Insight into Routine Clinical Data on Trough Concentrations: The Case of Tacrolimus in Chronic Kidney Disease. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-13 Eman El-Khateeb, Rajkumar Chinnadurai, Jokha Al Qassabi, Daniel Scotcher, Adam S Darwich, Philip A Kalra, Amin Rostami-Hodjegan
Routine therapeutic drug monitoring (TDM) relies heavily on measuring trough drug concentrations. Trough concentrations are affected not only by drug bioavailability and clearance, but also by various patient and disease factors and the volume of distribution. This often makes interpreting differences in drug exposure from trough data challenging. This study aimed to combine the advantages of top-down
-
Long-Term Intake of Linezolid Elevates Drug Exposure and Reduces Drug Clearance and Elimination in Adults With Drug-Resistant Pulmonary Tuberculosis. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-06 Shanmugam Murugaiha Jeyakumar, Namrata K Bhui, Neeta Singla, Sudha Vilvamani, Muthu Vijayalakshmi Mariappan, Chandrasekaran Padmapriyadarsini, Anuj K Bhatnagar, Rajesh Solanki, Rathinam Sridhar
Pharmacokinetic (PK) studies are critical for dose optimization, and there is a paucity of linezolid (LZD) PK data for prolonged use in drug-resistant tuberculosis (DR-TB). Therefore, the authors evaluated the pharmacokinetics of LZD at two-time intervals in DR-TB during long-term use.
-
Pharmacokinetic/Pharmacodynamic Target Attainment of Tigecycline in Patients with Hepatic Impairment in a Real-World Setting. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-05 Xiaoxuan Yang, Lu Jin, Xuemei Luo, Shurun An, Min Wang, Huaijun Zhu, Yujie Zhou, Hang Liu
This study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) target attainment of various tigecycline dosing regimens in real-world patients with impaired liver function.
-
Oxycodone, Morphine, and Fentanyl in Patients With Chronic Pain: Proposal of Dose-Specific Concentration Ranges. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-05 Cecilie Hasselø Thaulow, Arne Helland, Ulf Erik Kongsgaard, Gudrun Høiseth
Interpreting opioid concentrations is challenging because of the lack of reference ranges. Therefore, the authors aimed to propose dose-specific concentration ranges in serum for oxycodone, morphine, and fentanyl in patients with chronic pain, based on concentration measurements from a large number of patients and supported by theoretical pharmacokinetic calculations and previously published concentrations
-
Changes in Psychotropic Drug Blood Levels After SARS-CoV-2 Vaccination: A Two-Center Cohort Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-06-05 Maxim Kuzin, Fabian Gardin, Markus Götschi, Franziskos Xepapadakos, Wolfram Kawohl, Erich Seifritz, Antje Trauzeddel, Michael Paulzen, Georgios Schoretsanitis
Limited evidence from case reports suggests that coronavirus disease 2019 (COVID-19) vaccination may interact with the treatment outcomes of psychiatric medications. Apart from clozapine, reports on the effect of COVID-19 vaccination on other psychotropic agents are scarce. This study aimed to investigate the impact of COVID-19 vaccination on the plasma levels of different psychotropic drugs using
-
Cobicistat as a Potential Booster of Ponatinib and Dasatinib Exposure in a CML Patient: A Case Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-05-30 Susan Hofman, Daan J Touw, Bart F R Span, Thijs H Oude Munnink
The authors present a case of a 57-year-old patient with chronic myeloid leukemia who was treated with ponatinib and subsequently treated with dasatinib. The patient showed a major molecular response; however, the BCR-ABL1 signal increased with low ponatinib and dasatinib trough concentrations. Cobicistat was used as a pharmacokinetic booster to increase ponatinib and dasatinib exposure, as opposed
-
Delayed Lithium Reintoxication in a Case of Severe Multidrug Intoxication: A Case Study. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-05-30 Jiayi Liang, Christiaan J van den Bout, Tessa M Bosch, Lieke Mitrov-Winkelmolen
The authors present a case of severe multidrug intoxication following massive ingestion of lithium, nortriptyline, aripiprazole, lorazepam, and temazepam. After initial treatment, serum lithium levels decreased significantly. However, 28 hours post ingestion, recurrent elevated lithium levels were observed, and serum lithium level increased 0.71 mmol/L in 12 hours. The intensivist consulted a hospital
-
Diverse Drug Classes Partition into Human Sweat: Implications for Both Sweat Fundamentals and for Therapeutic Drug Monitoring. Ther. Drug Monit. (IF 2.5) Pub Date : 2023-05-30 Theresa Ruwe, Evyn White, Aidan S Zebertavage, David Runnoe, Dan Fay, Henry Daumeyer, Timothy S Tracy, Kara Fay Uchtman, Gavi Begtrup, Yuchan Yuan, Jason Heikenfeld, William A Buggele
Therapeutic drug monitoring to optimize drug therapy typically relies on the inconvenience of repeated plasma sampling. Sweat is a potential alternative biofluid convenient for sampling. However, limited information exists regarding the range of drugs excreted in sweat and their correlation with plasma concentrations. This study evaluated drugs in sweat and plasma of an ambulatory clinical cohort.